(19)
(11) EP 3 318 632 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
14.12.2022 Bulletin 2022/50

(45) Mention of the grant of the patent:
26.10.2022 Bulletin 2022/43

(21) Application number: 16818051.1

(22) Date of filing: 30.06.2016
(51) International Patent Classification (IPC): 
C12N 15/09(2006.01)
G01N 33/53(2006.01)
C12Q 1/6886(2018.01)
 C12N 5/09(2010.01)
G01N 33/574(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 15/09; G01N 33/53; G01N 33/574; C12Q 1/6886; C12Q 2600/158
(86) International application number:
PCT/JP2016/069529
(87) International publication number:
WO 2017/002943 (05.01.2017 Gazette 2017/01)

(54)

MARKER FOR HETEROGENEITY OF CANCER TISSUE, AND USE THEREOF

MARKER DER HETEROGENITÄT VON KREBSGEWEBE UND VERWENDUNG DAVON

MARQUEUR DE L'HOMOGÉNÉITÉ D'UN TISSU CANCÉREUX ET UTILISATION DUDIT MARQUEUR

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 01.07.2015 JP 2015133033

(43) Date of publication of application:
09.05.2018 Bulletin 2018/19

(73) Proprietor: Fujita Academy
Toyoake-shi, Aichi 470-1192 (JP)

(72) Inventors:
  • SAYA, Hideyuki
    Tokyo 160-8582 (JP)
  • ARIMA, Yoshimi
    Tokyo 160-8582 (JP)
  • SEMBA, Takashi
    Tokyo 160-8582 (JP)

(74) Representative: Schnappauf, Georg 
ZSP Patentanwälte PartG mbB Hansastraße 32
80686 München
80686 München (DE)


(56) References cited: : 
WO-A1-2006/053442
WO-A1-2013/116144
CN-A- 101 993 944
JP-A- 2009 513 161
JP-A- 2013 507 987
 WO-A1-2010/064702
WO-A1-2014/144804
JP-A- 2007 527 220
JP-A- 2012 525 159
US-A1- 2014 100 121
   
  • N. NAVIN ET AL: "Inferring tumor progression from genomic heterogeneity", GENOME RESEARCH, vol. 20, no. 1, 1 January 2010 (2010-01-01), pages 68-80, XP055210315, ISSN: 1088-9051, DOI: 10.1101/gr.099622.109
  • LUCIANO G MARTELOTTO ET AL: "Breast cancer intra-tumor heterogeneity", BREAST CANCER RESEARCH, CURRENT MEDICINE GROUP LTD, GB, vol. 16, no. 3, 20 May 2014 (2014-05-20), page 210, XP021203826, ISSN: 1465-5411, DOI: 10.1186/BCR3658
  • YANG, X. ET AL.: 'Microcirulatory fraction (MCF1) as a potential imaging marker for tumor heterogeneity in breast cancer.' MAGNETIC RESONANCE IMAGING vol. 30, no. 8, October 2012, ISSN 1541-2016 pages 1059 - 1067, XP055342304
  • YIP, C. ET AL.: 'Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy.' RADIOLOGY vol. 270, no. 1, January 2014, ISSN 0033-8419 pages 141 - 148, XP055342306
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).